News

Gentium has reported a total revenue of E2.61m for the second quarter ended June 30, 2009, compared to E1.86m for the second quarter of 2008. The increase is

Intarcia Therapeutics (Intarcia) has initiated enrollment for a phase 2 study comparing its proprietary drug candidate ITCA 650 (DUROS continuous delivery of exenatide) with Byetta, an FDA-approved twice-daily

Johnson & Johnson and Elan Corporation (Elan) have reported that Janseen Alzheimer Immunotherapy has completed the acquisition of substantially all of the assets and rights of Elan related

GlaxoSmithKline (GSK) and XenoPort have reported top-line results from a phase IIb clinical trial evaluating the safety and efficacy of GSK1838262/XP13512 (gabapentin enacarbil) for neuropathic pain associated with

YM BioSciences has reported that nimotuzumab has been approved for marketing in Mexico. YM BioSciences also announced that it has enrolled the first two patients in its randomised,

The Linde Group has launched its research and development (R&D) centre in Shanghai, taking the lead in the development of new high technology industrial gas applications and solutions

Tianyin Pharmaceutical (Tianyin) has received the Good Manufacturing Practices Certificate for pharmaceutical products (GMP Certificate) from the State Food and Drug Administration (SFDA) in China. Reportedly, based on

Abbott is in the process of launching, more than 40 sustainable packaging initiatives across its nutrition, pharmaceutical and medical products businesses to meet its goal of a 5%

Smith & Nephew’s Advanced Wound Management division, announced that it is launching two extensions to the ALLEVYN Ag range of dressings; ALLEVYN Ag Gentle Border and ALLEVYN Ag